Neal Walker - Aug 9, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
INTERIM PRESIDENT AND CEO, Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Aug 9, 2024
Transactions value $
$31,355
Form type
4
Date filed
8/13/2024, 04:15 PM
Previous filing
Aug 5, 2024
Next filing
Sep 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise $31.4K +43.5K +3.32% $0.72 1.36M Aug 9, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Employee Stock Option (right to buy) Options Exercise $0 -43.5K -100% $0.00* 0 Aug 9, 2024 Common Stock 43.5K $0.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.